PVH
TEVA icon

Psagot Value Holdings’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Psagot Value Holdings’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,442
Closed -$208K – 485
2023
Q4 		$208K Buy
+5,442
New +$50.8K 0.09% 161
2023
Q2 		– Sell
-300
Closed -$3K – 624
2023
Q1 		$3K Buy
+300
New +$2.97K ﹤0.01% 389
2022
Q2 		– Sell
-18,328
Closed -$172K – 366
2022
Q1 		$172K Buy
+18,328
New +$153K 0.04% 213
2021
Q4 		– Sell
-14,207
Closed -$138K – 448
2021
Q3 		$138K Sell
14,207
-522,116
-97% -$4.89M 0.02% 287
2021
Q2 		$5.31M Sell
536,323
-4,776,164
-90% -$50.6M 0.19% 82
2021
Q1 		$61.3M Buy
5,312,487
+385,583
+8% +$4.42M 1.38% 22
2020
Q4 		$47.5M Buy
4,926,904
+440,810
+10% +$4.22M 1.1% 26
2020
Q3 		$40.4M Buy
4,486,094
+4,128,139
+1,153% +$43.7M 1.02% 24
2020
Q2 		$4.41M Sell
357,955
-912,728
-72% -$10.3M 0.12% 92
2020
Q1 		$11.4M Buy
1,270,683
+1,195,498
+1,590% +$12.2M 0.47% 55
2019
Q4 		$737K Buy
75,185
+930
+1% +$8.3K 0.02% 196
2019
Q3 		$511K Sell
74,255
-34,200
-32% -$262K 0.02% 193
2019
Q2 		$1M Sell
108,455
-280
-0.3% -$3.38K 0.04% 169
2019
Q1 		$1.71M Buy
108,735
+2,121
+2% +$37.4K 0.07% 145
2018
Q4 		$1.64M Sell
106,614
-12,084
-10% -$248K 0.08% 143
2018
Q3 		$2.56M Sell
118,698
-14,693
-11% -$341K 0.11% 100
2018
Q2 		$3.24M Sell
133,391
-199,616
-60% -$4.07M 0.15% 83
2018
Q1 		$5.69M Sell
333,007
-1,193,637
-78% -$23.3M 0.25% 70
2017
Q4 		$28.9M Buy
1,526,644
+15,949
+1% +$240K 1.26% 25
2017
Q3 		$26.6M Buy
1,510,695
+853,603
+130% +$19.2M 1.12% 26
2017
Q2 		$21.8M Buy
657,092
+497,237
+311% +$15.4M 0.94% 31
2017
Q1 		$5.13M Buy
159,855
+21,331
+15% +$728K 0.22% 64
2016
Q4 		$5.02M Sell
138,524
-110,069
-44% -$4.39M 0.22% 66
2016
Q3 		$11.4M Sell
248,593
-821,412
-77% -$42.9M 0.48% 45
2016
Q2 		$53.7M Buy
1,070,005
+481,820
+82% +$25.7M 2.32% 12
2016
Q1 		$31.5M Buy
588,185
+1,263
+0.2% +$74.1K 1.31% 20
2015
Q4 		$38.5M Sell
586,922
-11,063
-2% -$684K 1.38% 17
2015
Q3 		$33.8M Buy
597,985
+89,514
+18% +$5.8M 1.22% 19
2015
Q2 		$30.1M Buy
+508,471
New +$31.4M 0.95% 23

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Psagot Value Holdings's TEVA Position: Q1 2024 in Review

Psagot Value Holdings sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2024, closing a stake of 5,442 shares — an estimated $208K sold.

Psagot Value Holdings first reported a position in TEVA in Q2 2015 and held it in 29 quarters. The position peaked at $61.3M in Q1 2021. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Psagot Value Holdings reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2024 after selling out during the quarter.
  • Psagot Value Holdings sold 5,442 Teva Pharmaceutical Industries Limited shares in Q1 2024, an estimated $208K.
  • Psagot Value Holdings first reported a position in Teva Pharmaceutical Industries Limited in Q2 2015 and held it in 29 quarters.
  • Psagot Value Holdings's Teva Pharmaceutical Industries Limited position peaked at $61.3M in Q1 2021.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2024.

Based on Psagot Value Holdings's 13F filing for Q1 2024, filed 15 May 2024.